In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Endologix' Marriage of Convenience

Executive Summary

Endologix needed cash, Radiance Medical needed a new market. Each found what it needed in a merger which will give Endologix the resources to develop its AAA graft line while helping Radiance segue out of a coronary brachytherapy market all but decimated by drug-eluting stents.

You may also be interested in...



Endologix Rebuilds A European Network

It's not unusual for small device companies to begin early to build a European distribution network. But AAA graft company Endologix has had to do so three times in three years.

Novoste: Radiation's Glowing Promise

At this year's American College of Cardiology meeting, radiation pioneer Novoste squeezed in at the last minute with data from its START clinical trial proving the safety and efficacy of radiation in treating in-stent restenosis. Novoste's path to this promising opportunity has been long and costly and fraught with regulatory challenges, epitomized by a European launch that, company officials say, was misunderstood by most industry observers. To be sure, radiation still has its skeptics and critics, but Novoste and its supporters believe that the START data underscores that beta radiation represents the best hope for future restenosis treatments. The real significance of the START data isn't that it proves that radiation works--it's that, for now, the future debate about radiation is likely to be defined by Novoste.

Endologix Inc.

Endologix is using creative financing to develop a one-piece AAA device.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL055695

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel